Report Published: "Serbia Pharmaceuticals & Healthcare Report Q1 2014"
Despite the fact that per capita expenditure on drugs is increasing steadily, Serbia's pharmaceutical market as a whole is still underdeveloped in regional terms. As the country continues its economic convergence with developed Europe, drug consumption is expected to rise. However, financial inefficiencies within the health insurance system compel the National Health Insurance Institution (RZZO) to frequently make changes to coverage and pharmaceutical pricing. The state must seriously consider expanding its pharmaceutical budget to improve care and patient outcomes, especially...
View full press release